Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 5Genitourinary 4Gastrointestinal 4Thoracic 3Sarcoma 3Lymphoid 3Gynecologic 3Plasma cell 2Other hematologic neoplasm 2NET 2Endocrine 2Head & Neck 1Breast 1

Conditions

Neuroendocrine Tumors 169Carcinoma, Neuroendocrine 73Thyroid Neoplasms 52Pheochromocytoma 45Thyroid Carcinoma, Anaplastic 42Thyroid Cancer, Papillary 42Adrenocortical Carcinoma 40Carcinoid Tumor 39Paraganglioma 35Adenocarcinoma, Follicular 33Neoplasm Metastasis 29Neoplasms 28Somatostatinoma 26Adenoma, Islet Cell 26Insulinoma 22Carcinoma, Medullary 22Carcinoma, Islet Cell 22Pancreatic Neoplasms 21Pituitary Neoplasms 20Sarcoma 19Glucagonoma 19Gastrinoma 19Gastro-enteropancreatic neuroendocrine tumor 16Head and Neck Neoplasms 15Colorectal Neoplasms 14Multiple Endocrine Neoplasia Type 1 13Neuroblastoma 12Carcinoma, Renal Cell 12Carcinoma, Non-Small-Cell Lung 12Vipoma 11

Interventions

lutetium Lu 177 dotatate 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Disease Progression × Endocrine × Clear all
NCT04954820 2026-02-05

ReLUTH

Institut du Cancer de Montpellier - Val d'Aurelle

Phase 2 Recruiting
146 enrolled
EndocrineNET

Neuroendocrine Tumors, Disease Progression

NCT06472388 2024-06-25

EVENET

AC Camargo Cancer Center

Phase 2 Recruiting
100 enrolled
EndocrineNET

Carcinoid Tumor, Adenoma, Islet Cell, Neuroendocrine Tumors, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡